Preclinical evidences, sustaining a potential involvement of LKB1 loss in inducing an immune-suppressive tumor microenvironment, have been confirmed by the clinical evidence that showed that has co-mutated KRAS-LKB1 advanced NSCLC obtained limited benefits from immunotherapy [7]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.